Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature

Conclusion: A complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine. Keywords: familial Mediterranean fever, interleukin-1, amyloidosis, colchicine
Source: Biologics: Targets and Therapy - Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research